Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + whole-cell pertussis + hepatitis b + haemophilus influenzae type b conjugate vaccine
- Development stage
- Approved
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **combination vaccine** that protects against five serious diseases: **diphtheria**, **tetanus**, **pertussis (whooping cough)**, **hepatitis B**, and **Haemophilus influenzae type b (Hib)**[2]. It contains toxoids or antigens from each pathogen: diphtheria toxoid, tetanus toxoid, whole-cell Bordetella pertussis, hepatitis B surface antigen, and conjugated Hib antigen. The vaccine stimulates the body's immune system to produce antibodies against all five pathogens, providing immunity and preventing illness. It is mainly used in infants and young children, typically in national immunization programs for routine childhood vaccination. The developer and manufacturer depend on the brand; UNICEF, WHO, and GAVI have procured and supported its adoption widely in lower- and middle-income countries[2]. The mechanism of action is immunological priming: each component elicits antigen-specific immune responses leading to the production of protective antibodies (neutralization of toxins, blocking pathogen entry, and opsonization of bacteria). The Hib component is conjugated to a carrier protein to boost immunogenicity. Primary indications are the prevention of diphtheria, tetanus, pertussis, hepatitis B infection, and invasive disease by Haemophilus influenzae type b in infants and young children.
- Brand names
- Shan5Shan-5Shan 5PentabioPentavacQuinvaxem
- Other names
- pentavalent vaccine5-in-1 vaccinediphtheria-tetanus-whole-cell pertussis-hepatitis B-haemophilus influenzae type b vaccine
02
Targets
Diphtheria toxinHBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on diphtheria + tetanus + whole-cell pertussis + hepatitis b + haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + whole-cell pertussis + hepatitis b + haemophilus influenzae type b conjugate vaccine.